Augmentin as Primary Therapy for Pneumonia in Long-Term Care Facilities

Rationale for Combination Therapy in Long-Term Care Settings

Long-term care facility residents with pneumonia have a pathogen spectrum that resembles hospital-acquired pneumonia (HAP) and healthcare-associated pneumonia (HCAP), with higher prevalence of resistant organisms 2, 3
Common pathogens in nursing home-acquired pneumonia include Staphylococcus aureus, enteric gram-negative rods, Streptococcus pneumoniae, and Pseudomonas species 3
Elderly residents of long-term care facilities with severe pneumonia often have methicillin-resistant S. aureus, gram-negative enterics, and Pseudomonas species 3
Monotherapy with Augmentin would fail to cover atypical pathogens like Mycoplasma pneumoniae or Chlamydophila pneumoniae 1

For patients in long-term care facilities, combination therapy is recommended: Augmentin (amoxicillin-clavulanate) plus a macrolide (azithromycin or clarithromycin) or doxycycline 4, 1
Dosing options include 500 mg/125 mg three times daily, 875 mg/125 mg twice daily, or 2000 mg/125 mg twice daily 1
For patients with risk factors for drug-resistant S. pneumoniae, high-dose amoxicillin-clavulanate (2000 mg/125 mg twice daily) is preferred 1

The American Thoracic Society and Infectious Diseases Society of America guidelines recommend combination therapy with a β-lactam (such as amoxicillin-clavulanate) plus a macrolide for hospitalized non-ICU patients 4, 5
Studies show that combined oral therapy with amoxicillin and a macrolide is preferred for patients requiring hospital admission for clinical reasons 6
Combination therapy improves outcomes in patients with pneumonia, particularly those with more severe disease 7

Residents of nursing homes and extended care facilities are at higher risk for healthcare-associated pneumonia with resistant pathogens 2
If the patient has received antibiotics within the past 3 months, an alternative from a different class should be selected 1
For patients with recent β-lactam use, consider a respiratory fluoroquinolone instead 1

Using Augmentin as monotherapy will miss atypical pathogens that are common in pneumonia 1
Standard-dose Augmentin may be insufficient in areas with high prevalence of drug-resistant S. pneumoniae 1
Failing to consider recent antibiotic exposure, which increases the risk of resistant organisms 1
Not accounting for the higher prevalence of resistant organisms in long-term care settings compared to community settings 2, 3